Wexford Capital LP Has $1.49 Million Stock Position in Nuvation Bio Inc. (NYSE:NUVB)

Wexford Capital LP increased its stake in Nuvation Bio Inc. (NYSE:NUVB - Free Report) by 930.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 651,767 shares of the company's stock after acquiring an additional 588,500 shares during the period. Wexford Capital LP owned approximately 0.26% of Nuvation Bio worth $1,493,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. FMR LLC lifted its stake in Nuvation Bio by 1.4% during the third quarter. FMR LLC now owns 29,238,871 shares of the company's stock valued at $66,957,000 after purchasing an additional 416,932 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Nuvation Bio by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 7,534,148 shares of the company's stock valued at $27,424,000 after acquiring an additional 219,533 shares during the last quarter. State Street Corp grew its holdings in shares of Nuvation Bio by 4.8% in the 3rd quarter. State Street Corp now owns 4,166,441 shares of the company's stock worth $9,541,000 after acquiring an additional 191,031 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Nuvation Bio by 4.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,394,015 shares of the company's stock worth $3,192,000 after purchasing an additional 60,590 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Nuvation Bio by 415.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,018,329 shares of the company's stock valued at $2,975,000 after purchasing an additional 820,669 shares during the last quarter. Institutional investors and hedge funds own 61.67% of the company's stock.

Nuvation Bio Price Performance

NUVB traded up $0.08 on Friday, reaching $2.85. 2,189,946 shares of the company traded hands, compared to its average volume of 2,654,901. The stock's 50 day moving average price is $2.53 and its 200-day moving average price is $2.86. Nuvation Bio Inc. has a 52-week low of $1.27 and a 52-week high of $4.16. The company has a market cap of $959.22 million, a price-to-earnings ratio of -1.31 and a beta of 1.46.

Nuvation Bio (NYSE:NUVB - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The company had revenue of $0.73 million during the quarter. As a group, equities research analysts forecast that Nuvation Bio Inc. will post -0.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Royal Bank of Canada lifted their price target on Nuvation Bio from $5.00 to $6.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Wedbush restated an "outperform" rating and set a $5.00 price target on shares of Nuvation Bio in a report on Thursday, November 7th. Finally, HC Wainwright lowered their price objective on shares of Nuvation Bio from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Monday, September 16th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $6.60.

Insider Activity

In other news, Director Robert Mashal bought 100,000 shares of the company's stock in a transaction that occurred on Tuesday, October 8th. The shares were purchased at an average price of $2.20 per share, for a total transaction of $220,000.00. Following the acquisition, the director now directly owns 100,000 shares of the company's stock, valued at $220,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 5.07% of the stock is currently owned by insiders.

Nuvation Bio Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.